Background:

RET (ret proto-oncogene), a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in RET are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for RET. Additional transcript variants have been described but their biological validity has not been confirmed.

Alternative names:

RET; CDHF12; CDHR16; PTC; RET51; Proto-oncogene tyrosine-protein kinase receptor Ret; Cadherin family member 12; Proto-oncogene c-Ret

Clonality:

Polyclonal

Reactivity:

Human,Mouse,Rat

Source:

Rabbit

Isotype:

Request info at info@sobekbio.com

Immunogen:

Synthesized peptide derived from human Ret around the phosphorylation site of Y905.

Concentration:

1mg/ml

Applications:

IHC, IF, ELISA

Recommende dilutions:

Request info at info@sobekbio.com

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.4. Store at -20°C. Avoid repeated freeze-thaw cycles.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com